Key facts
- KaloCyte’s last known valuation is $24.7M (Jun 2025).
- It has raised $5.7M across 1 recorded rounds; the latest was Accelerator/Incubator in Jan 2020.
- Notable investors include Springboard Enterprises, United States Department of War, TEDCO, Johnson & Johnson Innovation - JLABS, BioGenerator Ventures — 21 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for KaloCyte
Funding rounds
1 roundsAbout KaloCyte
Developer of a red blood cell substitute designed to support oxygen delivery in trauma care settings. The company offers context-dependent oxygen release with reduced vasoconstriction and minimized methemoglobin formation, enabling emergency physicians, military medical teams, and critical care providers to treat traumatic hemorrhage when banked blood is unavailable or unsuitable.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Employees
- 12
- Website
- kalocyte.com/
- Ownership
- Privately Held (backing)
KaloCyte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KaloCyte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KaloCyte in its N-PORT filings yet. We sweep new filings monthly.